Last reviewed · How we verify
FLOVENT 250mcg — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
FLOVENT 250mcg (FLOVENT 250mcg) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| FLOVENT 250mcg TARGET | FLOVENT 250mcg | GlaxoSmithKline | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- FLOVENT 250mcg CI watch — RSS
- FLOVENT 250mcg CI watch — Atom
- FLOVENT 250mcg CI watch — JSON
- FLOVENT 250mcg alone — RSS
Cite this brief
Drug Landscape (2026). FLOVENT 250mcg — Competitive Intelligence Brief. https://druglandscape.com/ci/flovent-250mcg. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing